Tuberculosis biomarker and surrogate endpoint research roadmap

Payam Nahid, Jussi Saukkonen, William R. Mac Kenzie, John L. Johnson, Patrick P J Phillips, Janet Andersen, Erin Bliven-Sizemore, John T. Belisle, W. Henry Boom, Annie Luetkemeyer, Thomas B. Campbell, Kathleen D. Eisenach, Richard Hafner, Jeffrey L. Lennox, Mamodikoe Makhene, Susan Swindells, M. Elsa Villarino, Marc Weiner, Constance Benson, William Burman

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation of a specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.

Original languageEnglish (US)
Pages (from-to)972-979
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number8
StatePublished - Oct 15 2011

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Tuberculosis biomarker and surrogate endpoint research roadmap'. Together they form a unique fingerprint.

Cite this